Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date
8.1.2026 22:30:00 CET | Business Wire | Press Release
The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/
Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation).
The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company.
“The Citation CJ3 Gen2 delivers an unmatched experience from day one—thanks to its exceptional range, payload and efficiency, combined with new productivity and comfort features,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Customers like Shannon and Dave will undoubtedly appreciate this aircraft, our most comprehensive Gen2 investment to date.”
Certified by the Federal Aviation Administration in October 2025, the aircraft was designed based on customer feedback via a Customer Advisory Board made up of owners, pilots and mechanics helping to create the ultimate aircraft experience. This feedback was key in every detailed enhancement in the aircraft, from cockpit to cabin.
“After extensive consideration of the competition, there was no equal for handling, service and support, training and reliability in the entry level jet category than the CJ3 Gen2,” said Shannon Day. “When we decided to upgrade our mission capabilities, staying in the Citation family was an easy decision. The CJ3 Gen2 is a great next step in my aviation journey and I’m looking forward to the advances in this aircraft like autothrottles, an externally serviceable lavatory and more legroom for a 6’3” pilot.”
The cockpit in the CJ3 Gen2 provides an extra 4.5 inches (11.4 cm) of legroom for the pilot, improving entry and egress from the pilot’s seat before and after flight. It offers a proven and trusted avionics system with the latest Garmin G3000 software and hardware, including:
- Garmin Autothrottles to reduce pilot workload and provide flight-envelope protection
- Intuitive touchscreen interface via Garmin Touchscreen Controllers
- GDL60 for aircraft connectivity, including remote transmission of flight plans, automatic database updates as well as wireless transmission of aircraft diagnostic data
The fully customizable luxury interior allows customers to create the ideal environment for their specific mission with seating for up to 10 occupants. For added convenience, the Citation CJ3 Gen2 includes an externally serviceable lavatory.
“As a Cessna Citation owner since 2007, the brand has consistently earned my trust with a proven heritage, superior reliability and one of the strongest service and support networks in the industry,” Mecartney added. “The aftermarket support has always been responsive, efficient and predictable—which is invaluable as an owner-pilot. Choosing the CJ3 Gen2 felt like a natural continuation of a relationship and an aircraft lineage that I’ve relied on for nearly two decades.”
Textron Aviation delivers unmatched Aftermarket support through a global network designed to keep customers flying. With 20 company-owned service centers worldwide, 21 Authorized Service Facilities (ASFs) for Citation jets and more than 80 Mobile Service Units (MSUs), expert help is always within reach. The company’s expanded parts distribution network—with seven distribution centers and 17 stockrooms globally—offers same-day shipping and online ordering for over 150,000 unique part numbers. Textron Aviation Parts Distribution is backed by a team of more than 600 dedicated professionals and an expanded global customer support team, providing customers with the assistance they need wherever they are. The Aftermarket team offers 24/7 AOG support, delivering fast, reliable solutions that minimize downtime and maximize aircraft availability.
With a maximum range of 2,040 nautical miles (3,778 kilometers) and a maximum payload of 2,135 lbs. (968.4 kg), the Citation CJ3 Gen2 offers excellent range, payload and field performance to enable pilots to achieve a variety of missions in extensive conditions.
Learn more about the iconic Citation CJ3 family at cessna.txtav.com.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special mission, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable and flexible flight. For more information, visit www.txtav.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems. For more information, visit: www.textron.com.
Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108455097/en/
Contacts
Media Contact
Kate Flavin
+1.316.252.7780
kflavin@txtav.com
txtav.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftxtav.com%2F&e
sheet=54392438&newsitemid=20260108455097&lan=en-US&anchor=txtav.com&index=7&md5=
4882e31d291070744a83ed90568d947a
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom